SCHEMBL789564

SCHEMBL789564

Cc1ccc(Nc2nc(C(=O)N3CCC(C)CC3)cs2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TRPC3 Q13507 13/20 1.00
TRPC6 Q9Y210 13/20 1.00
TSHR P16473 1/20 0.72
TRPA1 O75762 1/20 0.67
CACNA1C Q13936 1/20 0.67
SCN5A Q14524 1/20 0.67
TRPV1 Q8NER1 1/20 0.67
TRPV4 Q9HBA0 1/20 0.67
MEN1 O00255 1/20 0.66
KMT2A Q03164 1/20 0.66
GAA P10253 1/20 0.62
MAPT P10636 1/20 0.54
MAPK1 P28482 1/20 0.54
GFER P55789 1/20 0.54
MDM2 Q00987 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL789873 0.87 TRPC3 (0.81) TRPC3TRPC6TSHRTRPA1CACNA1C
SCHEMBL790396 0.81 TRPC3 (0.77) TRPC3TRPC6TSHRTRPA1CACNA1C
SCHEMBL789503 0.80 TRPC3 (1.00) TRPC3TRPC6TSHRTRPA1CACNA1C
SCHEMBL789091 0.80 TRPC3 (0.78) TRPC3TRPC6TSHRMEN1KMT2A
SCHEMBL798999 0.77 TRPC3 (0.63) TRPC3TRPC6TSHRTRPA1CACNA1C
SCHEMBL806632 0.77 TRPC3 (0.63) TRPC3TRPC6TSHRTRPA1CACNA1C
SCHEMBL10087864 0.77 TRPC3 (0.81) TRPC3TRPC6TSHRTRPA1CACNA1C
SCHEMBL806598 0.77 TRPC3 (0.74) TRPC3TRPC6TSHRMEN1KMT2A
SCHEMBL789898 0.77 TRPC3 (0.75) TRPC3TRPC6TSHRTRPA1CACNA1C
SCHEMBL5200233 0.76 MAPT (0.68) TRPC3TRPC6TRPA1CACNA1CSCN5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012037351-A1 COMPOUNDS GLAXOSMITHKLINE LLC (US) 2012-03-22 WO claimed
US-20230137816-A1 ADMINISTRATION OF CALCIUM CHANNEL TRPC6 INHIBITORS USING BALLOONS, STENTS OR OTHER MEDICAL DEVICES DEUTSCHES HERZZENTRUM MUENCHEN DES FREISTAATES BAYERN (DE) 2023-05-04 US disclosed
US-20230137816-A1 ADMINISTRATION OF CALCIUM CHANNEL TRPC6 INHIBITORS USING BALLOONS, STENTS OR OTHER MEDICAL DEVICES DEUTSCHES HERZZENTRUM MUENCHEN DES FREISTAATES BAYERN (DE) 2023-05-04 US disclosed
WO-2021160625-A1 ADMINISTRATION OF CALCIUM CHANNEL TRPC6 INHIBITORS USING BALLOONS, STENTS OR OTHER MEDICAL DEVICES KLINIKUM RECHTS DER ISAR (DE) 2021-08-19 WO disclosed
WO-2012037351-A1 COMPOUNDS GLAXOSMITHKLINE LLC (US) 2012-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230137816-A1 ADMINISTRATION OF CALCIUM CHANNEL TRPC6 INHIBITORS USING BALLOONS, STENTS OR OTHER MEDICAL DEVICES TRPC6, TRPC1, ORAI1 TRPC3 6/4885TRPC6 1/4885TSHR 3703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.